Stemtech Corp. Files Q3 2024 10-Q Report

TL;DR

Stemtech Corp. filed its Q3 2024 10-Q. All systems go.

AI Summary

Stemtech Corp. filed its 10-Q for the quarterly period ended September 30, 2024. The company, formerly known as Globe Net Wireless Corp., is incorporated in Nevada and headquartered in Naples, Florida. Its principal executive offices are located at 4851 Tamiami Trail North, Suite 200, Naples, FL 34103, with a business phone number of (954) 715-6000.

Why It Matters

This filing provides investors with the latest financial performance and operational details of Stemtech Corp. for the third quarter of 2024, crucial for understanding the company's current standing.

Risk Assessment

Risk Level: low — This is a routine quarterly filing and does not contain immediate, high-impact news.

Key Players & Entities

• Stemtech Corp. (company) — Registrant
• September 30, 2024 (date) — Quarterly period end date
• Globe Net Wireless Corp. (company) — Former company name
• Nevada (jurisdiction) — State of incorporation
• Naples, FL (location) — Principal executive offices location
• 4851 Tamiami Trail North Suite 200 (address) — Principal executive offices address
• (954) 715-6000 (phone_number) — Business phone number

FAQ

Key Financial Figures

• $0.001 — te: 134,754,232 shares of common stock, $0.001 par value, issued and outstanding as of
• $3,378,331 — atements, the Company had a net loss of $3,378,331 and $5,431,979 respectively, for the pe
• $5,431,979 — ompany had a net loss of $3,378,331 and $5,431,979 respectively, for the period ended Sept
• $30,436,682 — e Company had an accumulated deficit of $30,436,682 at September 30, 2024. These factors ra
• $0.00 — cash balance amounted to approximately $0.00. Inventory The Company values invent

Filing Documents

• stemtech_10q-093024.htm (10-Q) — 463KB
• stemtech_x3101.htm (EX-31.1) — 11KB
• stemtech_x3102.htm (EX-31.2) — 11KB
• stemtech_x3201.htm (EX-32.1) — 5KB
• stemtech_x3202.htm (EX-32.2) — 4KB
• 0001683168-24-008267.txt ( ) — 495KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION 4 Item 1. Consolidated Financial Statements 4 Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (unaudited) 4 Consolidated Statements of Operations and Comprehensive Loss for the nine months ended September 30, 2024 and 2023 (unaudited) 5 Consolidated Statements of Stockholders’ Equity (Deficit) for the nine months ended September 30, 2024 and 2023 (unaudited) 6 Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (unaudited) 7

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) 8 Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 4.

Controls and Procedures

Controls and Procedures 29

— OTHER INFORMATION

PART II — OTHER INFORMATION Item 1 Legal Proceeding 30 Item 1A

Risk Factors

Risk Factors 30 Item 2. Recent Sale of Unregistered Securities 30 Item 3. Defaults Upon Senior Securities 30 Item 4. Mine Safety Disclosures 30 Item 5. Other Information 30 Item 6. Exhibits 31

SIGNATURES

SIGNATURES 32 2 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere herein may address or relate to future events and expectations and as such constitutes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking · the size and growth of the potential markets for our products and the ability to serve those markets; · our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing; · the rate and degree of market acceptance of any of our products; · our expectations regarding competition; · our anticipated growth strategies; · our ability to attract or retain key personnel; · our ability to establish and maintain development partnerships; · regulatory developments in the U.S. and foreign countries, especially those related to change in, and enforcement of, cannabis laws; · our ability to obtain and maintain intellectual property protection for our products; and · the anticipated trends and challenges in our business and the market in which we operate.

Forward-looking statements,

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended December 31, 2023 (filed on July 10 th , 2024) entitled “Risk Factors” as well as in our other public filings. In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason. 3

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Stemtech Corporation Consolidated Balance Sheets (Unaudited) September 30, 2024 December 31, 2023 ASSETS CURRENT ASSETS: Cash $ 260,344 $ 114,166 Accounts receivable, net 256,498 61,494 Inventory, net 187,661 48,325 Prepaid expenses and other current assets 74,083 176,725 TOTAL CURRENT ASSETS 778,586 400,710 Property and equipment, net – 10,056 Intangible assets, net 2,376,158 2,710,568 Other long term assets – – Long term deposits 16,932 23,708 Operating lease right-of-use assets - net – 70,820 Goodwill 467,409 467,409 Intercompany – – TOTAL ASSETS $ 3,639,085 $ 3,683,271 LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable and accrued expenses $ 4,947,398 $ 2,708,906 Notes payable 2,105,240 1,889,321 Convertible debentures, net of discount 1,959,364 1,596,960 Operating lease liabilities - current – 66,866 Deferred revenues 192,685 56,039 Factoring liability 384,916 143,944 Derivative liability – – TOTAL CURRENT LIABILITIES 9,589,603 6,462,036 Notes payable - Long term – – Operating lease liabilities - noncurrent – – Other long term liabilities – – TOTAL LIABILITIES 9,589,603 6,462,036 COMMITMENTS AND CONTINGENCIES (Note 10) STOCKHOLDERS' EQUITY Common stock - $0.001 par value; 200,000,000 shares authorized; 116,769,707 and 104,988,853 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 122,597 104,989 Additional paid in capital 26,012,705 24,726,722 Accumulated other comprehensive loss (908,720 ) 190,503 Accumulated deficit (30,434,472 ) (27,061,486 ) Stemtech Corporation shareholders’ deficit (5,207,890 ) (2,039,272 ) Non-controlling interest in subsidiaries (742,628 ) (739,493 ) Net loss – – TOTAL STOCKHOLDERS EQUITY (5,950

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) Note 1 – Organization and Basis of Presentation Stemtech Corporation and its Subsidiaries (collectively, the “ Company ”) was incorporated in the State of Nevada, USA on September 4, 2009 under the previous name Globe Net Wireless Corp. On November 19, 2021, the Company adopted an Amendment to its Articles changing the name of the Corporation to Stemtech Corporation in the state of Nevada, and on April 14, 2022, FINRA gave final approval for said name change, as evidenced by the 8-K filed that date. Stemtech is a global network marketing company that develops science-based products that it believes supports wellness by helping the body maintain healthy stem cell physiology, also known as stem cell enhancers. Known as the Stem Cell Nutrition Company®, the Company is a pioneer in stem cell science, and believes it can demonstrate that adult stem cells function as the natural renewal system of the body. The Company believes its products enhance and support the work of the body’s stem cells by releasing more stem cells, helping to circulate them in the blood and migrate them into tissues, where they can perform their daily function of renewal for optimal health. Our mission is to enhance wellness and prosperity around the world. These products are marketed internationally by the Company’s subsidiaries and through independent distributors. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem® and OraStem® (Oral Health Care), and Cellect One® Rapid Renew Stem Cell Peptide Night Cream. On August 19, 2021, Stemtech Corporation (“ Stemtech ”), a Delaware corporation, entered into a Merger Agreement (the “ Merger Agreement ”) with Globe Net Wireless Corp. (“ Globe Net ” or “ GNTW ”). The merger was accounted for as a reverse acquisition and recapitalization in

View Full Filing

View this 10-Q filing on SEC EDGAR